Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Director departure
|
|
Chemomab Therapeutics Ltd. (ANCN)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 08/14/2023 |
6-K
| Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:|
Docs:
|
"6-K",
"Unaudited Audited Current assets Cash and cash equivalents 10,382 13,519 Short term bank deposits 16,207 26,374 Restricted cash 74 77 Other receivables and prepaid expenses 1,042 1,766 Total current assets 27,705 41,736 Non-current assets Long term prepaid expenses 646 733 Property and equipment, net 338 367 Operating lease right-of-use assets 160 227 Total non-current assets 1,144 1,327 Total assets 28,849 43,063 Current liabilities Trade payables 2,347 1,688 Accrued expenses 2,503 3,378 Employee and related expenses 1,867 1,560 Operating lease liabilities 108 123 Total current liabilities 6,825 6,749 Non-current liabilities Operating lease liabilities - long term 33 91 Total non-current liabilities 33 91 Commitments and contingent liabilities 3 Total liabilities 6,858 6,840 Shareholders'...",
"CAUTIONARY NOTE ABOUT FORWARD-LOOKING STATEMENTS",
"TEL AVIV, Israel, August 14, 2023 ─ Chemomab Therapeutics Ltd. , , a clinical stage biotechnology company developing innovative therapeutics to treat rare fibro-inflammatory diseases with high unmet need, today announced financial and operating results for the second quarter ended June 30, 2023, and provided a corporate update. “I am pleased to report that the company continued to make good progress during the second quarter,” said Adi Mor, PhD, co-founder, Chief Executive Officer and Chief Scientific Officer of Chemomab. “In June, the Board of Directors re-appointed me to the CEO position and re-appointed then Vice President of Finance Sigal Fattal as Chief Financial Officer. Our extensive prior experience in these roles and ongoing active involvement in company management have made..." |
|
| 08/08/2023 |
6-K
| Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]: |
| 07/05/2023 |
4
| Darvish Nissim (Director) has filed a Form 4 on Chemomab Therapeutics Ltd.|
Txns:
| Granted 20,572 options to buy
@ $1.7, valued at
$35k
Granted 6,857 options to buy
@ $1.62, valued at
$11.1k
Granted 6,820 options to buy
@ $3.53, valued at
$24.1k
Granted 11,884 options to buy
@ $27.26, valued at
$324k
Granted 10,123 options to buy
@ $0.8, valued at
$8.1k
|
|
| 07/03/2023 |
6-K
| Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]: |
| 06/16/2023 |
4
| Fatal Sigal (CFO) has filed a Form 4 on Chemomab Therapeutics Ltd.|
Txns:
| Granted 102,860 options to buy
@ $1.7, valued at
$174.9k
Granted 29,400 options to buy
@ $2.11, valued at
$62k
Granted 35,600 options to buy
@ $9.83, valued at
$349.9k
|
|
| 06/16/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 06/05/2023 |
3
| Fatal Sigal (CFO) has filed a Form 3 on Chemomab Therapeutics Ltd. |
| 05/19/2023 |
S-1/A
| Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend] |
| 05/11/2023 |
8-K
| Quarterly results |
| 05/11/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
| 03/23/2023 |
4
| Moses Alan Charles (Director) has filed a Form 4 on Chemomab Therapeutics Ltd.|
Txns:
| Granted 6,857 options to buy
@ $1.62, valued at
$11.1k
Granted 6,820 options to buy
@ $3.53, valued at
$24.1k
Granted 11,884 options to buy
@ $27.26, valued at
$324k
|
|
| 03/23/2023 |
4
| Nicaise Claude (Director) has filed a Form 4 on Chemomab Therapeutics Ltd.|
Txns:
| Granted 6,857 options to buy
@ $1.62, valued at
$11.1k
Granted 6,820 options to buy
@ $3.53, valued at
$24.1k
Granted 11,884 options to buy
@ $27.26, valued at
$324k
|
|
| 03/23/2023 |
4
| Cohen Neil Harris (Director) has filed a Form 4 on Chemomab Therapeutics Ltd.|
Txns:
| Granted 6,875 options to buy
@ $1.62, valued at
$11.1k
Granted 6,820 options to buy
@ $3.53, valued at
$24.1k
Granted 11,884 options to buy
@ $27.26, valued at
$324k
Granted 688 options to buy
@ $13.17, valued at
$9.1k
|
|
| 03/23/2023 |
4
| Darvish Nissim (Director) has filed a Form 4 on Chemomab Therapeutics Ltd.|
Txns:
| Granted 6,857 options to buy
@ $1.62, valued at
$11.1k
Granted 6,820 options to buy
@ $3.53, valued at
$24.1k
Granted 11,884 options to buy
@ $27.26, valued at
$324k
Granted 10,123 options to buy
@ $0.8, valued at
$8.1k
|
|
| 03/21/2023 |
S-1/A
| Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend] |
| 03/21/2023 |
ARS
| Form ARS - Annual Report to Security Holders: |
| 03/20/2023 |
10-K
| Annual Report for the period ended December 31, 2022 |
| 02/22/2023 |
S-1/A
| Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend] |
| 01/13/2023 |
S-1
| Form S-1 - General form for registration of securities under the Securities Act of 1933: |
| 01/11/2023 |
8-K
| Quarterly results |
| 01/05/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 01/05/2023 |
SC 13D/A
| Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] |
| 01/05/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 01/03/2023 |
8-K
| Quarterly results |
| 11/29/2022 |
8-K/A
| Quarterly results |
| 11/18/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 11/17/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 11/17/2022 |
SC 13D/A
| Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] |
| 11/16/2022 |
8-K
| Quarterly results |
| 11/15/2022 |
3
| Form 3 - Initial statement of beneficial ownership of securities: |
| 11/14/2022 |
8-K
| Quarterly results |
| 11/10/2022 |
10-Q
| Quarterly Report for the period ended September 30, 2022 |
| 08/15/2022 |
S-8
| Form S-8 - Securities to be offered to employees in employee benefit plans: |
| 08/12/2022 |
10-Q
| Quarterly Report for the period ended June 30, 2022 |
|
|
|